<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122416</url>
  </required_header>
  <id_info>
    <org_study_id>M139</org_study_id>
    <nct_id>NCT05122416</nct_id>
  </id_info>
  <brief_title>Optimization of Spleen VCTE Examinations With FibroScan</brief_title>
  <official_title>Optimization of Spleen VCTE Examinations With FibroScan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Echosens</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Echosens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an European, prospective, interventional, and multicenter clinical investigation&#xD;
      which main objective is to develop a spleen examination dedicated to overweight or obese&#xD;
      patients and assess its applicability. It will take place in 4 sites (1 site in the&#xD;
      Netherlands, 2 sites in Spain and 1 site in Romania) to include a total of 500 patients&#xD;
      (adults and children).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There will be 6 different groups of patients depending on the spleen to skin distance and the presence or absence of splenomegaly. Every patient in every group will do an ultrasound and 2 FibroScan exams. The differences between Group 1 (1a and 1b), Group 2 (2a and 2b) and Group 3 (3a and 3b) are the probes that will be used to do the FibroScan.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of the spleen stiffness measurement (SSM) exam with the XL probe, defined with at least 8 valid measurements after the exam quality control</measure>
    <time_frame>At baseline visit</time_frame>
    <description>The success rate is calculated with the number of valid measurements vs the total measurements done by the operator for every exam. The FibroScan will automatically analyze the measurement and based on some validity criteria will define the measurement as &quot;valid&quot; (will lead to a reliable SSM measurement) or &quot;invalid&quot; (will lead to a non-reliable SSM measurement).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate of the spleen stiffness measurement (SSM) exam with the S probe, defined with at least 8 valid measurements after the exam quality control.</measure>
    <time_frame>At baseline visit</time_frame>
    <description>The success rate is calculated with the number of valid measurements vs the total measurements done by the operator for every exam. The FibroScan will automatically analyze the measurement and based on some validity criteria will define the measurement as &quot;valid&quot; (will lead to a reliable SSM measurement) or &quot;invalid&quot; (will lead to a non-reliable SSM measurement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of the spleen stiffness measurement (SSM) exam with the optimized M probe, defined with at least 8 valid measurements after the exam quality control.</measure>
    <time_frame>At baseline visit</time_frame>
    <description>The success rate is calculated with the number of valid measurements vs the total measurements done by the operator for every exam. The FibroScan will automatically analyze the measurement and based on some validity criteria will define the measurement as &quot;valid&quot; (will lead to a reliable SSM measurement) or &quot;invalid&quot; (will lead to a non-reliable SSM measurement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the applicability with the Spleen Targeting Tool (STT) and the automatic depth adaptation mode enabled.</measure>
    <time_frame>At baseline visit</time_frame>
    <description>This will be tested with unilateral Wilcoxon signed rank test comparing success rates with and without STT and with and without automatic depth adaptation.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Spleen; Fibrosis</condition>
  <arm_group>
    <arm_group_label>Group 1a: SSD&lt;15mm and with splenomegaly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Spleen to Skin Distance less than 15mm and who present a splenomegaly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b: SSD&lt;15mm and without splenomegaly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Spleen to Skin Distance less than 15mm and who does not present a splenomegaly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a : 15&lt;SSD&lt;25mm and with splenomegaly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Spleen to Skin Distance between 15 and 25 mm and who present a splenomegaly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b : 15&lt;SSD&lt;25mm and without splenomegaly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Spleen to Skin Distance between 15 and 25 mm and who does not present a splenomegaly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3a: SSD≥25mm and with splenomegaly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Spleen to Skin Distance higher than 25 mm and who present a splenomegaly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3b: SSD≥25mm and without splenomegaly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Spleen to Skin Distance higher than 25 mm and who does not present a splenomegaly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroScan examination (S)</intervention_name>
    <description>A FibroScan examination with the Exploratory S probe.</description>
    <arm_group_label>Group 1a: SSD&lt;15mm and with splenomegaly</arm_group_label>
    <arm_group_label>Group 1b: SSD&lt;15mm and without splenomegaly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroScan examination (M)</intervention_name>
    <description>A FibroScan examination with the Optimized M probe.</description>
    <arm_group_label>Group 2a : 15&lt;SSD&lt;25mm and with splenomegaly</arm_group_label>
    <arm_group_label>Group 2b : 15&lt;SSD&lt;25mm and without splenomegaly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroScan examination (XL)</intervention_name>
    <description>A FibroScan examination with the Exploratory XL probe.</description>
    <arm_group_label>Group 3a: SSD≥25mm and with splenomegaly</arm_group_label>
    <arm_group_label>Group 3b: SSD≥25mm and without splenomegaly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroScan examination (Standard M)</intervention_name>
    <description>A FibroScan examination with the Standard M probe.</description>
    <arm_group_label>Group 1a: SSD&lt;15mm and with splenomegaly</arm_group_label>
    <arm_group_label>Group 1b: SSD&lt;15mm and without splenomegaly</arm_group_label>
    <arm_group_label>Group 2a : 15&lt;SSD&lt;25mm and with splenomegaly</arm_group_label>
    <arm_group_label>Group 2b : 15&lt;SSD&lt;25mm and without splenomegaly</arm_group_label>
    <arm_group_label>Group 3a: SSD≥25mm and with splenomegaly</arm_group_label>
    <arm_group_label>Group 3b: SSD≥25mm and without splenomegaly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult or pediatric patient able to give written informed consent (parents/legal tutors&#xD;
             in case of minor patients),&#xD;
&#xD;
          2. Patient affiliated to the healthcare system&#xD;
&#xD;
          3. Adult or children patient followed for a liver disease, with or without splenomegaly&#xD;
             and having a spleen to skin distance (SSD) measurement performed during the screening&#xD;
             ultrasound exam.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Vulnerable patient- other than pediatric patients&#xD;
&#xD;
          2. Patients with ascites&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert de Knegt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Rotterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Llorca</last_name>
    <phone>+33144827850</phone>
    <email>anne.llorca@echosens.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Caroline Gourmelon</last_name>
    <phone>+33144827850</phone>
    <email>marie-caroline.gourmelon@echosens.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert de Knegt, PhD</last_name>
      <email>r.deknegt@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Institute of Gastroenterology and Hepatology &quot;Octavian Fodor&quot; (IRGH)</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <contact>
      <last_name>Horia Stefanescu, Dr</last_name>
      <email>drhstefanescu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Luis Calleja, PhD</last_name>
      <email>joseluis.calleja@uam.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Miriam Romero, Dr</last_name>
      <email>mromerop@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FibroScan</keyword>
  <keyword>Vibration Control Transient Elastography</keyword>
  <keyword>Spleen Stiffness Measurement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

